Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Lyra Therapeutics (LYRA) over the last 4 years, with Q3 2025 value amounting to $34182.0.

  • Lyra Therapeutics' Gains from Sales and Divestitures rose 2265.24% to $34182.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $34182.0, marking a year-over-year increase of 2265.24%. This contributed to the annual value of $86574.0 for FY2024, which is 112956.97% up from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Gains from Sales and Divestitures is $34182.0, which was up 2265.24% from $15104.0 recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' Gains from Sales and Divestitures peaked at $365121.0 during Q1 2025, and registered a low of $1302.0 during Q2 2022.
  • Moreover, its 4-year median value for Gains from Sales and Divestitures was $15104.0 (2025), whereas its average is $47385.2.
  • The largest annual percentage gain for Lyra Therapeutics' Gains from Sales and Divestitures in the last 5 years was 121013.31% (2025), contrasted with its biggest fall of 4580.36% (2025).
  • Lyra Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $1953.0 in 2022, then surged by 260.52% to $7041.0 in 2023, then soared by 1129.57% to $86574.0 in 2024, then tumbled by 60.52% to $34182.0 in 2025.
  • Its Gains from Sales and Divestitures was $34182.0 in Q3 2025, compared to $15104.0 in Q2 2025 and $365121.0 in Q1 2025.